The December 2012 issue:
- Letter from Sara Rafsky
- How to Survive a Plague
- 2012 Fundraisers
- International AIDS Conference
- New Staff Members
- Reports from the Front
- In Memoriam: Peter Diffly
Tuberculosis Research and Development: 2012 Report on Tuberculosis Research Funding Trends, 2005–2011
November 14, 2012 – Now in its seventh year, TAG's Tuberculosis Research and Development: 2012 Report on Tuberculosis Research Funding Trends: 2005–2011 builds on seven years of investment data to report on annual funding trends and gaps among the leading TB R&D donors. The report analyzes current spending levels across six research areas to assess how they compare to the Stop TB Partnership’s Global Plan to Stop TB 2011–2015 R&D funding targets.
- TAG at 20 – Part II: On a Darkling Plain—The Years of Despair
The clinical science of AIDS before the discovery of highly active antiretroviral therapy (HAART) in 1995–96, and how TAG responded to the needs of people with AIDS.
- Only Stronger U.S. Leadership Can End the AIDS Epidemic
- Cure-Related Research at AIDS 2012
- The Future of TB in the United States: Going, or Growing?
- Getting to Zero—Join the Movement!
- GeneXpert Rapid TB Test Price Reduced in Historic Agreement
2012 PIPELINE REPORT
HIV, Hepatitis C Virus (HCV), and Tuberculosis (TB) Drugs, Diagnostics, Vaccines, and Preventive Technologies in Development
July 22, 2012 – Visit our new website www.PipelineReport.org to:
- Read the report online
- Download individual chapters as PDFs
- Browse for specific information by agent
- TAG's Early Campaigns:
Reforming NIH AIDS Research, Boosting the Budget, and Revitalizing the Basic Science of HIV Infection
- The Odyssey of Therapeutic Vaccines for HIV
- What You Don’t Know, You Can Sell:
Merck’s Cavalier Attitude Towards the Welfare of HIV/HCV Coinfected Patients
- Does Obama’s 2013 Budget Herald the End of PEPFAR?
- Childhood TB Advocacy Picks Up Steam
April 2012 – These HCV protease inhibitor fact sheets describe how each drug should be used, how likely treatment is to be successful, common side effects, drugs that cannot be used with each HCV protease inhibitor, and information about co-pay assistance and patient assistance programs.
Being Brave: Stories of Children with Drug-Resistant Tuberculosis
March 2012 – When it comes to drug-resistant tuberculosis (DR-TB), the global community is failing to “get it right.” Millions of people around the world suffer from this dangerous, yet treatable, infectious disease. Yet, in over a decade, less than 1% of those with DR-TB have been diagnosed and treated. Children bear a disproportionate burden of this disease, and are far less likely than adults with DR-TB to have access to appropriate care. This collection gives voice to the children from around the world featured in it, and to the thousands more like them who face the challenges of fighting DR-TB every day. It is also a global call to action. These stories invite all of us to join children with DR-TB and their families and caregivers in the struggle for better diagnosis and treatment. It is the first step toward “getting it right” for children with TB.